Education
About Us
Working with TipRanks
Follow Us
Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ:ARTV
RESEARCH TOOLSreports
ARTV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.47 - $17.31
Previous CloseN/A
Volume23.16K
Average Volume (3M)88.62K
Market Cap
$70.35M
Enterprise Value-$92.33M
Total Cash (Recent Filing)$142.37M
Total Debt (Recent Filing)$13.22M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
Nov 18, 2025EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.87
Shares Outstanding24,425,762
10 Day Avg. Volume136,127
30 Day Avg. Volume88,616
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.16
Forecast
1Y Price Target
$14.50Price Target Upside403.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical TrialsArtiva is advancing AlloNK, a non-genetically modified, cord blood-derived natural killer cell therapy, for the treatment of various B cell mediated autoimmune diseases.
Regulatory ProgressThe FDA cleared the Phase IIa IND without requiring patient hospitalization, offering initial validation of AlloNK's value.
Safety Data ReleaseBy the end of 2025, the company plans to release initial safety data and announce a lead indication for continued development, which will be the first dataset evaluating AlloNK in autoimmune diseases.
Bears Say
Data ExpectationsEarly safety and translational data across various AID remains the next key driver for ARTV.
Enrollment ChallengesEnrollment changes and generating small datasets across indications don't live up to the initial bar set by Schett.
Artiva Biotherapeutics, Inc. News
ARTV FAQ
What was Artiva Biotherapeutics, Inc.’s price range in the past 12 months?
Artiva Biotherapeutics, Inc. lowest stock price was $1.47 and its highest was $17.31 in the past 12 months.
What is Artiva Biotherapeutics, Inc.’s market cap?
Artiva Biotherapeutics, Inc.’s market cap is $70.35M.
When is Artiva Biotherapeutics, Inc.’s upcoming earnings report date?
Artiva Biotherapeutics, Inc.’s upcoming earnings report date is Nov 18, 2025 which is in 58 days.
How were Artiva Biotherapeutics, Inc.’s earnings last quarter?
Artiva Biotherapeutics, Inc. released its earnings results on Aug 06, 2025. The company reported -$0.87 earnings per share for the quarter, missing the consensus estimate of -$0.806 by -$0.064.
Is Artiva Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Artiva Biotherapeutics, Inc.’s price is currently Undervalued.
Does Artiva Biotherapeutics, Inc. pay dividends?
Artiva Biotherapeutics, Inc. does not currently pay dividends.
What is Artiva Biotherapeutics, Inc.’s EPS estimate?
Artiva Biotherapeutics, Inc.’s EPS estimate is -0.87.
How many shares outstanding does Artiva Biotherapeutics, Inc. have?
Artiva Biotherapeutics, Inc. has 24,425,762 shares outstanding.
What happened to Artiva Biotherapeutics, Inc.’s price movement after its last earnings report?
Artiva Biotherapeutics, Inc. reported an EPS of -$0.87 in its last earnings report, missing expectations of -$0.806. Following the earnings report the stock price went down -8.014%.
Which hedge fund is a major shareholder of Artiva Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in ARTV
Artiva Biotherapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (403.47% Upside)
$14.50 (403.47% Upside)
Blogger Sentiment
Bullish
ARTV Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 3.7%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.44%
12-Months-Change
Fundamentals
Return on Equity
-86.18%
Trailing 12-Months
Asset Growth
123.14%
Trailing 12-Months
Company Description
Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.
ARTV Stock 12 Month Forecast
Average Price Target
$14.50
▲(403.47% Upside)
Technical Analysis
Ownership Overview
7.02% Insiders
4.14% Mutual Funds
64.56% Other Institutional Investors
23.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---